Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
a study on Breast Cancer Colon Cancer Colorectal Cancer Esophageal Cancer Stomach Cancer Head and Neck Cancer Kidney Cancer Lung Cancer Ovarian Cancer Pancreatic Cancer Solid Neoplasm Uterine Cancer Prostate Cancer Carcinoma Pancreatic Neoplasms Renal Cell Carcinoma Kidney Neoplasm
Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer, Carcinoma, Breast Neoplasms, Pancreatic Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Renal Cell Carcinoma, Kidney Neoplasms, Edetic Acid, Gallium 68 PSMA-11, Fluorodeoxyglucose F18, FAPI-46, Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG, Basic Science (68Ga-FAPi-46 PET/CT, 68Ga-PSMA-11 PET/CT)
Lead Scientist at UCLA
- Jeremie Calais
Nuclear medicine physician specialized in cancer imaging and theranostics. Associate Professor, Department of Molecular and Medical Pharmacology at UCLA Director, Theranostics Program, Ahmanson Translational Theranostics Division at UCLA Faculty Member of the Jonsson Comprehensive Cancer Center at UCLA. Faculty Member of the Institute of Urologic Oncology at UCLA.